Nanoparticles, capable of presenting multiple ligands to engage various immune cell types, enhance T-cell activation and therapeutic effects against malignant tumors in mice, when loaded with both anti-PD1 and anti-OX40 antibodies, compared to simple drug mixtures (Mi et al., 2018). Here, PDCD1 is linked to cancer.